Tumor suppressor immune gene therapy to reverse immunotherapy resistance

[1]  J. Nemunaitis,et al.  Analysis of Adenoviral p53 Gene Therapy Clinical Trials in Recurrent Head and Neck Squamous Cell Carcinoma , 2021, Frontiers in Oncology.

[2]  S. Gettinger,et al.  Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02). , 2020, Cancer discovery.

[3]  Vinay Prasad,et al.  Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs , 2019, JAMA network open.

[4]  Ø. Bruserud,et al.  S100 Proteins in Acute Myeloid Leukemia12 , 2018, Neoplasia.

[5]  F. Marincola,et al.  Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA) , 2018, Journal of Immunotherapy for Cancer.

[6]  M. Robinson,et al.  ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. , 2018, The Lancet. Oncology.

[7]  R. Bourgon,et al.  TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells , 2018, Nature.

[8]  J. Lunceford,et al.  IFN-&ggr;–related mRNA profile predicts clinical response to PD-1 blockade , 2017, The Journal of clinical investigation.

[9]  M. Lizano,et al.  SOX2 as a New Regulator of HPV16 Transcription , 2017, Viruses.

[10]  Zhilun Wang,et al.  Loss of Reelin suppresses cell survival and mobility in non-Hodgkin lymphoma. , 2017, Oncology reports.

[11]  S. Sheng,et al.  An Essential Role of Maspin in Embryogenesis and Tumor Suppression. , 2017, Cancer research.

[12]  E. Tartour,et al.  IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists , 2016, The Journal of Immunology.

[13]  Xiaoping Zhou,et al.  Nerve growth factor receptor negates the tumor suppressor p53 as a feedback regulator , 2016, eLife.

[14]  M. Rantalainen,et al.  Reprogramming Tumor-Associated Macrophages by Antibody Targeting Inhibits Cancer Progression and Metastasis. , 2016, Cell reports.

[15]  M. Addepalli,et al.  NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models , 2016, Clinical Cancer Research.

[16]  H. Hong,et al.  Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models , 2015, Cancer Immunology Research.

[17]  S. Sheng,et al.  Tumor suppressor maspin as a modulator of host immune response to cancer. , 2015, Bosnian journal of basic medical sciences.

[18]  J. Garcia-Vallejo,et al.  DC-SIGN: The Strange Case of Dr. Jekyll and Mr. Hyde. , 2015, Immunity.

[19]  J. Lunceford,et al.  Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature. , 2015 .

[20]  T. Gajewski,et al.  Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity , 2015, Nature.

[21]  J. Segovia,et al.  Gas1 is a pleiotropic regulator of cellular functions: from embryonic development to molecular actions in cancer gene therapy. , 2014, Mini reviews in medicinal chemistry.

[22]  S. Sheng,et al.  Maspin expression in prostate tumor elicits host anti-tumor immunity , 2014, Oncotarget.

[23]  J. Roth,et al.  Tp53 gene therapy for cancer treatment and prevention , 2013 .

[24]  Vijay S. Pande,et al.  Exploiting a natural conformational switch to engineer an Interleukin-2 superkine , 2012, Nature.

[25]  J. Grutters,et al.  IL1RN genetic variations and risk of IPF: a meta-analysis and mRNA expression study , 2012, Immunogenetics.

[26]  S. O. Mueller,et al.  A Low-Toxicity IL-2–Based Immunocytokine Retains Antitumor Activity Despite Its High Degree of IL-2 Receptor Selectivity , 2011, Clinical Cancer Research.

[27]  J. Roth,et al.  Biomarkers Predict p53 Gene Therapy Efficacy in Recurrent Squamous Cell Carcinoma of the Head and Neck , 2009, Clinical Cancer Research.

[28]  M. Olivier,et al.  Recent advances in p53 research: an interdisciplinary perspective , 2009, Cancer Gene Therapy.

[29]  M. Keane.  The role of chemokines and cytokines in lung fibrosis , 2008, European Respiratory Review.

[30]  M. A. van de Wiel,et al.  Expression of Pla2g2a prevents carcinogenesis in Muc2‐deficient mice , 2008, Cancer science.

[31]  H. Grabsch,et al.  Inhibition of gastric cancer invasion and metastasis by PLA2G2A, a novel beta-catenin/TCF target gene. , 2008, Cancer research.

[32]  N. Kaminski,et al.  Idiopathic Pulmonary Fibrosis: Aberrant Recapitulation of Developmental Programs? , 2008, PLoS medicine.

[33]  T. Waldmann,et al.  Preassociation of IL-15 with IL-15Rα-IgG1-Fc Enhances Its Activity on Proliferation of NK and CD8+/CD44high T Cells and Its Antitumor Action1 , 2008, The Journal of Immunology.

[34]  R. Eeles,et al.  p53 therapy in a patient with Li-Fraumeni syndrome , 2007, Molecular Cancer Therapeutics.

[35]  Xin Li,et al.  Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells , 2006, Oncogene.

[36]  Antje Prasse,et al.  A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. , 2006, American journal of respiratory and critical care medicine.

[37]  B Nebiyou Bekele,et al.  Aberrant promoter methylation and silencing of laminin-5-encoding genes in breast carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  Robert Louis Stevenson,et al.  The strange case of Dr Jekyll and Mr Hyde and other tales of terror , 2002 .

[39]  D. Mercola,et al.  Use of wild‐type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53 , 1995, Molecular carcinogenesis.

[40]  J. Roth,et al.  High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. , 1994, Cancer gene therapy.

[41]  E. Grimm,et al.  Human interleukin 2 analogues that preferentially bind the intermediate-affinity interleukin 2 receptor lead to reduced secondary cytokine secretion: implications for the use of these interleukin 2 analogues in cancer immunotherapy. , 1993, Cancer research.